Matrix metalloprotease selective peptide substrates cleavage within hydrogel matrices for cancer chemotherapy activation

Peptides

Volumn 29, Issue 11, 2008, Pages 1965-1973

  Tauro, Jovita R ^a   Lee, Bao Shiang ^a   Lateef, Syed S ^a   Gemeinhart, Richard A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Cancer; Drug activation; Drug targeting; Hydrogel; Prodrug

Indexed keywords

CISPLATIN; GELATINASE A; GELATINASE B; MACROGOL; PLATINUM DERIVATIVE;

AMINO ACID SEQUENCE; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGEL; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS; HYDROGELS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; PEPTIDES; PLATINUM; SUBSTRATE SPECIFICITY;

EID: 54049142842     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2008.06.021     Document Type: Article

References (38)

1. Anandhi U., Holbert T., Lueng D., and Sharp P.R. Platinum and palladium imido and oxo complexes with small natural bite angle diphosphine ligands. Inorg Chem 42 4 (2003) 1282-1295
2. Barltrop J.A., Owen T.C., Cory A.H., and Cory J.G. 5-(3-Carboxymethoxyphenyl)-2-(4,5-dimethylthiazolyl)-3-(4-sulfophenyl)tetrazolium, inner salt (MTS) and related analogs of 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) reducing to purple water-soluble formazans as cell viability indicators. Bioorg Med Chem Lett 1 11 (1991) 611-614
3. Boudvillain M., Dalbies R., Aussourd C., and Leng M. Intra-strand crosslinks are not formed in the reaction between transplatin and native DNA-relation with the clinical inefficiency of transplatin. Nucleic Acids Res 23 13 (1995) 2381-2388
4. Brooks P.C., Stromblad S., Sanders L.C., vonSchalscha T.L., Aimes R.T., StetlerStevenson W.G., et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alphaV beta3. Cell 85 5 (1996) 683-693
5. Canal T., and Peppas N.A. Correlation between mesh size and equilibrium degree of swelling of polymeric networks. J Biomed Mater Res 23 10 (1989) 1183-1193
6. Chintala S.K., Tonn J.C., and Rao J.S. Matrix metalloproteases and their biological function in human gliomas. Int J Dev Neurosci 17 5-6 (1999) 495-502
7. Coussens L.M., Fingleton B., and Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295 (2002) 2387-2392
8. Davis K.A., and Anseth K.S. Controlled release from crosslinked degradable networks. Crit Rev Ther Drug Car Sys 19 4-5 (2002) 385-423
9. Desoize B. Metals and metal compounds in cancer treatment. Anticancer Res 24 3A (2004) 1529-1544
10. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2 5 (2003) 347-360
11. Elkins P.A., Ho Y.S., Smith W.W., Janson C.A., D'Alessio K.J., McQueney M.S., et al. Structure of the C-terminally truncated human proMMP9, a gelatin-binding matrix metalloproteinase. Acta Crystallogr D-Biol Crystallogr 58 (2002) 1182-1192
12. Forsyth P.A., Wong H., Laing T.D., Rewcastle N.B., Morris D.G., Muzik H., et al. Gelatinase-a (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (Mt1-Mmp) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 79 11-12 (1999) 1828-1835
13. Golla E.D., and Ayres G.H. Spectrophotometric determination of platinum with o-phenylenediamine. Talanta 20 (1973) 199-210
14. Gregg R.W., Molepo J.M., Monpetit V.J., Mikael N.Z., Redmond D., Gadia M., et al. Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 10 5 (1992) 795-803
15. Hartmann J.T., and Lipp H.-P. Toxicity of platinum compounds. Expert Opin Pharmacother 4 6 (2003) 889-901
16. Hern D.L., and Hubbell J.A. Incorporation of adhesion peptides into nonadhesive hydrogels useful for tissue resurfacing. J Biomed Mater Res 39 2 (1998) 266-276
17. Morgunova E., Tuuttila A., Bergmann U., Isupov M., Lindqvist Y., Schneider G., et al. Structure of human pro-matrix metalloprotease-2: activation mechanism revealed. Science 284 5420 (1999) 1667-1670
18. Nagase H., and Fields G.B. Human matrix metalloprotease specificity studies using collagen sequence-based synthetic peptides. Biopolymers 40 (1996) 399-416
19. Overall C.M., and Kleifeld O. Tumour microenvironment - opinion - validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6 3 (2006) 227-239
20. Peppas N.A., and Mikos A.G. Preparation methods and structure of hydrogels. In: Peppas N.A. (Ed). Hydrogels in medicine and pharmacy (1986), CRC Press, Boca Raton 1-27
21. Peppas N.A., Keys K.B., Torres-Lugo M., and Lowman A.M. Poly(ethylene glycol)-containing hydrogels in drug delivery. J Control Release 62 1-2 (1999) 81-87
22. Rao J.S., Yamamoto M., Mohaman S., Gokaslan Z.L., Fuller G.N., Stetler-Stevenson W.G., et al. Expression and localization of 92 kDa Type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 14 1 (1996) 12-18
23. Ringsdorf H. Structure and properties of pharmacologically active polymers. J Polym Sci Polym Symp 51 (1975) 135-153
24. Rundhaug J.E. Matrix metalloproteinases and angiogenesis. J Cell Mol Med 9 2 (2005) 267-285
25. Sawaya R.E., Yamamoto M., Gokaslan Z.L., Wang S.W., Mohaman S., Fuller G.N., et al. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 14 1 (1996) 35-42
26. Strongin A.Y. Mislocalization and unconventional functions of cellular MMPs in cancer. Cancer Metastasis Rev 25 1 (2006) 87-98
27. Takahara P.M., Rosenzweig A.C., Frederick C.A., and Lippard S.J. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377 6550 (1995) 649-652
28. Tanihara M., Suzuki Y., Nishimura Y., Suzuki K., and Kakimaru Y. Thrombin-sensitive peptide linkers for biological signal-responsive drug release systems. Peptides 19 3 (1998) 421-425
29. Tauro J.R., and Gemeinhart R.A. Peptide-based targeted activation of platinates by matrix metalloproteases. Neuro-oncology 6 4 (2004) 335-336
30. Tauro J.R., and Gemeinhart R.A. Matrix metalloprotease triggered delivery of cancer chemotherapeutics from hydrogel matrices. Bioconjug Chem 16 5 (2005) 1133-1139
31. Tauro J.R., and Gemeinhart R.A. Extracellular protease activation of chemotherapeutics from hydrogel matrices: a new paradigm for local chemotherapy. Mol Pharm 2 5 (2005) 435-438
32. Tauro J.R., and Gemeinhart R.A. Development of amine-containing polymeric particles. J Biomater Sci Polym Ed 16 10 (2005) 1233-1244
33. Thornton P.D., McConnell G., and Ulijn R.V. Enzyme responsive polymer hydrogel beads. Chem Commun 47 (2005) 5913-5915
34. Turk B.E., Huang L.L., Piro E.T., and Cantley L.C. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol 19 (2001) 661-667
35. Vartak D., and Gemeinhart R.A. Matrix metalloproteases: underutilized targets for drug delivery. J Drug Targeting 15 1 (2007) 1-21
36. Watkins A.W., and Anseth K.S. Investigation of molecular transport and distributions in poly(ethylene glycol) hydrogels with confocal laser scanning microscopy. Macromolecules 38 4 (2005) 1326-1334
37. Westphal M., Hilt D.C., Bortey E., Delavault P., Olivares R., Warnke P., et al. A phase III trial of local chemotherapy with biodegradable carmustine (BCNU) wafers in patients with primary malignant glioma. Neuro-oncology 5 2 (2003) 79-88
38. Yan X., and Gemeinhart R.A. Cisplatin delivery from poly(acrylic acid-co-methyl methacrylate) microparticles. J Control Release 106 1-2 (2005) 198-208